Conceptual Aspects of Large Meta-Analyses with Publicly Available Microarray Data: A Case Study in Oncology by Schmidberger, Markus et al.
Bioinformatics and Biology Insights 2011:5 13–39
doi: 10.4137/BBI.S5537
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Bioinformatics and Biology Insights
CASe reporT
Bioinformatics and Biology Insights 2011:5  13
conceptual Aspects of Large Meta-Analyses with publicly 
Available Microarray Data: A case study in Oncology
Markus Schmidberger, Sabine Lennert and Ulrich Mansmann
Division of Biometrics and Bioinformatics, IBe, University of Munich, 81377 Munich, Germany.  
Corresponding author email: mansmann@ibe.med.uni-muenchen.de
Abstract: Large public repositories of microarray experiments offer an abundance of biological data. It is of interest to use and to com-
bine the   available material to create new biological information and to develop a broader view on biological phenomena.
Meta-analyses recombine similar information over a series of experiments to sketch scientific aspects which were not accessible by 
each of the single experiments. Meta-analysis of high-throughput experiments has to handle methodological as well as technical chal-
lenges. Methodological aspects concern the identification of homogeneous material which can be combined by appropriate statistical 
procedures. Technical challenges come from the data management of large amounts of high-dimensional data, long computation time, 
as well as the handling of the stored phenotype data.
This paper compares in a meta-analysis of a large series of microarray experiments the interaction structure within selected pathways 
between different tumour entities. The feasibility of such a study is explored and a technical as well as a statistical framework for its 
completion is presented. Multiple obstacles were met during completion of this project. They are mainly related to the quality of the 
available data and influence the biological interpretation of the results derived.
The sobering experience of our study asks for combined efforts to improve the data quality in public repositories of high-throughput 
data. The exploration of the available data in large meta-analyses is limited by incomplete documentation of essential aspects of experi-
ments and studies, by technical deficiencies in the data stored, and by careless duplications of data.
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Introduction
Increasing insights into the pathogenesis of   malignant 
disorders and the detection of a rapidly rising num-
ber  of  molecular  alterations  gave  rise  to  the  hope 
that cancer specific genetic profiles might be gener-
ated that will define biologic subgroups as well as 
define   targets for direct specific therapeutic agents.1 
The  search  for  genomic  alterations  has  revealed  a 
huge heterogeneity not only within one histologically 
defined cancer entity but even within one individual 
tumour.2  The  heterogeneity  of  genomic  mutations, 
however,  becomes  less  complex  since  their  func-
tional effects merge in the alteration of a few, distinct 
  pathways, only.3 Hence, the understanding of cancer 
biology may be improved also by focusing on altera-
tions in pathway activities across tumour entities.
Rhodes  et  al4  developed  meta-analytic  tools  to 
characterize  a  common  transcriptional  profile  that 
is universally activated in most cancer types relative 
to the normal tissues from which they arise, likely 
reflecting  essential  transcriptional  features  of  neo-
plastic transformation. In addition, they characterized 
a transcriptional profile that is commonly activated 
in various types of undifferentiated cancer, suggest-
ing common molecular mechanisms by which cancer 
cells progress and avoid differentiation.
It is the goal of this study to explore the feasibility 
of a large cross-cancer meta-analysis based on high-
throughput gene expression microarray data (GEMA) 
to compare the interaction structure between mem-
bers  of  specific  pathways  across  relevant  tumour 
entities based on available gene expression microar-
ray  data  from  oncological  studies.  The  challenges 
of this   project are given by the quality of available 
data, the data management for the projected study, 
the   biostatistics/bioinformatics tools available for the 
analysis, and finally the strategy for interpreting the 
computational results.
Editorial policies and the idea to reuse the high-
throughput  gene  expression  data  for  validation  and 
new research questions triggered the creation of   public 
repositories.  The  MIAME  (Minimum  information 
about a microarray experiment) criteria5 formulate the 
necessary  conditions  for  verifying  and  reproducing 
results of microarray data analyses. MIAME compli-
ance assures a sensible reuse of public microarray data 
for the study of new questions: biological properties of 
the samples and phenotypes that were assayed need to 
be recorded along the data obtained from these assays.
At the moment there are three recommended inter-
national  repositories  to  archive  publication  related 
functional  genomic  data:6,7  ArrayExpress  (AE),8 
Gene Expression Omnibus (GEO),9 and the Center 
for Information Biology Gene Expression Database 
(CIBEX).10 GEO is currently the largest fully public 
gene expression resource.
Meta-analytic tools for GEMA are developed by 
many authors11 but mainly in the field of   differential 
gene  expression  and  profiling.  To  our  knowledge 
this paper is the first trying to do a meta-analysis of 
pathway specific network structures across tumour 
  entities. The structural comparison is motivated by 
the  discovery  of  different  relationships  between 
  cancer types.12 There is evidence for familial associa-
tions between acute myeloic leukemia and colorectal 
  cancer.13 Men with family history of breast cancer also 
have an increased risk of prostate cancer.14 Different 
leukemia derive from specified deregulation during 
the hematopoietic stem cell differentiation.15
Therefore,  the  interaction  structure  within  genes 
annotated  to  specific  pathways  is  explored  and 
  compared between eight human cancer entities. The 
cancer  entities  are  grouped  in  eight  tumour  groups: 
four solid tumours (breast, colon, prostate, lung) and 
four haemic tumours (ALL, AML, CLL,   Lymphoma). 
  Thirteen different KEGG pathways which are organized 
into three groups are   studied: Basic   cellular signalling 
pathways  (KEGG  ID  04110:  Cell  cycle,  04115: 
p53 signalling pathway, 04210:   Apoptosis, 04310: Wnt 
signalling pathway, 04512: ECM-  receptor interaction), 
Table 1. Number of experiments and samples in Geo (published data) and Ae database (27/02/2009). 
Database experiments samples experiments 
without FLeO
First data
Geo 11298 286645 4362 (39%) Jan 2001
Ae 7637 224947 1599 (21%) okt 2003
Abbreviation: FLeo, feature-level extraction output.Large meta-analysis in oncology
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disease specific pathways (05210:   Colorectal   cancer, 
05215:    Prostate  cancer,  05221:  Acute  myeloic 
leukaemia,  05223:    Non-small  cell  lung  cancer),  and 
pathways related to DNA repair (04150: mTOR sig-
nalling pathway, 03410: Base excision repair, 03420: 
Nucleotide excision repair, 03430: Mismatch repair).
The exploration of the communication   structure 
within a large set of genes is feasible by ignoring 
the dynamics of the complex biological system. The 
available  micorarray  measurements  represent  time 
averages  of  transcription  dynamics.  Conditional 
interaction graphs are used to infer their conditional 
correlation structure.16 An interpretation of the edges 
of these graphs will not be given. The interest consists 
in assessing evidence that these graphs are different 
with respect to edges between cancer entities.
The paper is an explorative study on a strategy how 
to combine publicly available data repositories, bioin-
formatic tools, and statistical concepts to the defined 
task. Therefore, an analysis pipeline for the intended 
problems is described. The adaption of data manage-
ment and related tools to assemble the data, to check its 
quality, and to perform the low and high level analysis 
for a very large set of microarrays is demonstrated. 
The results are presented. The paper is organized as 
follows: Section 2 describes material and methods, 
presents the data as well as the tools used for the low- 
and high-level analyses. Section 3 contains the results 
on  global  differences  in  the  conditional  correlation 
structure of thirteen pathways in eight cancer entities. 
We discuss our experiences and results in Section 4.
Materials and Methods
Microarray data set
Due  to  the  weekly  imports  from  GEO  to AE,  the 
data is taken from AE in order to facilitate the data 
  management process. The repositories are   dominated 
by  experiments  with  Affymetrix  Microarray  data 
of  the  ‘HG-U133A’  and  ‘HG-U133  Plus  2.0’  chip 
  platforms. In order to work with a sample with an 
uniform laboratory work-up, we concentrate on data 
from the ‘HG-U133A’ Affymetrix GeneChip. In order 
to avoid bias due to specific pre-processing of the raw 
data, the feature-level extraction output (FLEO) files 
(CEL files) are used.17 
All  experiments  from  AE  repository  available 
on February 27, 2009 and satisfying the following 
  selection criteria are included: FLEO data   available, 
more  than  10  arrays  have  chip  type  HGU133A, 
experiment  has  more  than  20  arrays,  50%  of  the 
arrays belong to one of the eight cancer   entities. Some 
experiments satisfying these criteria contain   identical 
arrays. For example the arrays from the   experiments 
‘E-GEOD-3910’  and  ‘E-GEOD-3911’  together  are 
identical to the arrays from the super series experi-
ment  ‘E-GEOD-3912’.  These    experiments  are  not 
included  in  the  study  to  avoid  duplicate  arrays. 
Thereby 23 experiments are excluded.
A  large  cancer  data  set  with  more  than  7000 
microarrays is built from about 60 public available 
experiments in the AE database. An overview of the 
selected experiments is available in the   Appendix. 
A  detailed  statistic  of  the  data  set  is  shown  in 
Table 2. Data from cell line experiments and from 
human patients are grouped together. Furthermore, 
cancer subtypes are combined to one cancer entity 
(eg, childhood ALL is included in the ALL cancer 
entity group).
The R language18 and the Bioconductor   project19 
are  chosen  as  the  computational  environment. 
In  order  to  handle  several  thousand  of  microar-
rays  for  the  low-  and  high-level  analyses  of  our 
Table 2. Statistic of available arrays for selected Arrayexpress experiments grouped by the eight cancer entities.
experiments Arrays HG-U133A Deficient Used
BreAST 20 3595 2454 (68%) 40 (1%) 1834 (51%)
ALL 12 1190 1140 (96%) 3 (0%) 916 (77%)
LUNG 7 537 398 (74%) 12 (2%) 386 (72%)
CoLoN 6 203 203 (100%) 6 (3%) 197 (97%)
proSTATe 5 475 418 (88%) 2 (0%) 416 (88%)
AML 4 726 563 (78%) 29 (4%) 534 (74%)
LYMpHoMA 4 335 335 (100%) 4 (1%) 331 (99%)
CLL 3 194 182 (94%) 5 (3%) 177 (91%)
61 7255 5693 (78%) 101 (1%) 4791 (66%)Schmidberger et al
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data   parallel computing is used.20,21 A   Bioconductor 
package  called  affyPara22,23  implements  parallel 
computing for pre-processing quality assessment of 
microarray data.
The tools ‘boxplot’ and ‘MA-plot’19 are used for 
quality  assessment  in  the  pre-processing  step.  If  an 
array is deficient in both assessments, it is marked as 
‘deficient’ and excluded. Sixty deficient arrays for solid 
cancer experiments and 41 deficient arrays for hae-
mic cancer experiments are excluded, which is about 
1% of the data. Due to duplicated arrays in different 
experiments (from one cancer entity) and several defi-
cient arrays, the set of arrays used in the analysis is 
smaller than all available arrays. For the breast cancer 
experiments only 51% can be used in the analysis and 
about 66% of all arrays. Therefore, the meta-analysis 
is executed on 4791 microarrays: 2833 arrays for solid 
tumours and 1958 arrays for haemic disease tumours.
phenotype data
No  detailed  data  on  the  phenotypes  of  the  patients 
included in the study was available due to lack of com-
pliance  with  MIAME  annotation  rules.  Even  basic 
information  like  sex  and  age  of  the  patients  is  not 
completely  available.  Detailed  information  on  basic 
features of the tumours are generally missing. Our find-
ings are summarized as follows: 47% of the patients 
are female and 18% male (36% missing), the median 
age is 55 (50% missing). All other variables, eg, tumour 
staging, are available for less than 20% of all arrays. 
Figure 1 shows the histogram of the age distribution for 
the haemic and solid cancer group. Since basic informa-
tion on the tumours are not available the tumour entities 
may represent quite inhomogeneous groups.
Data management
Sixty one single experiments and 7255 microarrays 
define the data set. Due to the large amount of CEL 
files and about 80 GB data volume, data management 
and storing is intricate. To make the data management 
feasible and reproducible, the raw data and processed 
data are saved in a general defined directory   structure 
on the local hard disk. For every cancer entity, a direc-
tory containing the files is created. The file structure is 
optimized for the data processing with the R language 
and for re-usability of intermediate results.
The R package called ArrayExpressData  Manage 
supports  the  data  management  of AE    experiments 
at  the  local  file  system.  It  uses  the    Bioconductor 
  package ArrayExpress24 to download data from the 
AE   database. Functions for different operations on 
the file structure are provided:   Standard   microarray 
processing  steps  (eg,  rma  parallel  and  serial 
  preprocessing) as well as functions for data structure 
cleaning, creating overview tables.
The  package  creates  automatically  the  data  set 
  generation script. Providing an R list structure object 
with the AE experiment IDs the complete data set can 
be regenerated from the AE data base. For the large 
cancer study the list object is available in the Appendix. 
  Therefore, the data set of our analysis is not submitted as 
new super-series data set to one of the public repositories. 
It (raw data and phenodata) is already available in the AE 
database and can easily constructed by the analyst from 
the data set generation script. It is straightforward to add 
new experiments to the analysis. For more details see 
the vignette of the package or the help files of the pack-
age. The package is available at the R-forge repository: 
http://AEDataManage.R-forge.R-project.org/.
Low-level analysis
The data is pre-processed in one run using the R pack-
ages ArrayExpressDataManage and affyPara. After 
quality control, normalization is achieved by the Robust 
Multichip Average25 [RMA] method. All analyses are 
parallelized and run on the 32 engine computer cluster 
at the IBE (LMU, Munich) offering a maximum of 128 
processors. Each machine runs on four processors and 
eight GB main memory and they are connected with a 
1 Gbit network. The complete RMA pre-processing of 











































Figure 1. Histogram of the age distribution for the hemic and solid cancer 
group.Large meta-analysis in oncology
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The data showed strong batch effects.   Correction for 
batch effects26,27 uses an empirical Bayes   framework 
as proposed by Johnson et al.27
High-level analysis
The PC-Algorithm28 is used to estimate the network 
structure  (conditional  correlation  structure)  within 
the set of genes annotated to each pathway for each 
cancer entities.
estimating graphs
Multivariate gene expression data is characterised 
by its mean value structure as well as its depen-
dence  or  correlation  structure.  While  the  first  is 
concerned  with  the  quantitative  amount  of  tran-
scription   activity, the second focuses on the map of 
direct influences between genes: does the transcrip-
tion activity of one gene influences the transcription 
activity of a   second gene freezing all other genes 
annotated to the   corresponding pathway on a fixed 
transcription level. An edge is drawn between two 
nodes (genes) if a direct influence is assessed. The 
PC-Algorithm   estimates such a graph from obser-
vational data.28,29
Thorough  validation  studies30  show   advantages 
of  the  PC-Algorithm  compared  to  competing 
  approaches31–35 especially for sparse graphs in terms 
of estimation quality (true and false discovery rates 
for edges) as well as computational speed.
The PC-Algorithm is run with α = 0.05. This is 
a good choice for a graph with less then 20% of the 
  maximal number of edges.28 This is a plausible assump-
tion for gene sets annotated to the KEGG pathways.
Comparing graphs
Graphs on the same set of nodes are compared by 
the Structural Hamming Distance (SHD). The SHD 
between two graphs is the number of edge inser-
tions, deletions or flips in order to transform one 
graph to the other. The smaller the SHD the bigger 
is the similarity between the two graphs. The SHD 
is symmetric and can be calculated by SHD = # of 
different edges in both graphs—# common edges in 
both graphs.
The  null-hypothesis  of  no  structural  difference 
between two tumour entities is tested by a permutation 
test. The test assesses if an observed SHD between 
two graphs is untypically large compared to the SHD 
  distribution under the null-hypothesis. This distribution 
results from comparing two   estimated graphs from 
two data sets which differ just by   random fluctuations. 
The permutation test is   carried out after standardizing 
the  transcription  values  of  genes    annotated  to  the 
  specific pathways. The mean value is substracted from 
the  individual    measurements  and  the  difference  is 
divided by the standard   deviation in each set of the two 
cancer entities which are   compared. The rejection of 
this null-hypothesis on a 5% significance level is con-
sidered as evidence the cell processes as captured by 
the specific set of pathway genes proves a differential 
dynamic between both tumour entities considered.
The resampling for the test procedure proceeds as 
follows:
•	 Choose the SHD to measure differential   conditional 
correlation structure between both graphs.
•	 Estimate  each  graph  by  the  PC-Algorithm  with 
α = 0.05 from the observed data and determine the 
SH Dobs between both graphs.
•	 For  resampling  step  i  permute  the  data  units 
between both data sets, estimate both graphs and 
calculate the specific SH Di (i = 1, …, R).
•	 Determine  a  permutation  P-value  by  pperm  = 
#{SH Dobs , SH Di}/R.
•	 Reject the null-hypothesis if pperm is smaller then 
0.05.
The data is resampled R = 500 times.
Permutation P-values below 0.01 are considered as 
evidence for a difference. Larger P-values are called 
marginal (P # 0.05) or not significant (P . 0.05).
Results
A total of 4791 microarrays was grouped into eight 
tumour entities (four solid tumours with a total of 
1958 arrays and four haemic tumours with a total of 
2833 arrays). The minimal sample sizes is 177 arrays 
for probes from CLL patients, the maximal   sample size 
is 1834 arrays for breast cancer tissue (see Table 2). 
The phenotype information on the individual tumour 
probes is very sparse and is not considered in the 
  following analysis.
Figure 2 shows the SHD for all six combinations 
of solid tumours (red triangles), all six   combinations 
of haemic tumours (black triangles), and for all 16 Schmidberger et al
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haemic-solid  combinations  (blue  triangles)  when 
conditional independence graphs are estimated for 
each entity and compared by SHD.
There is no obvious evidence in any pathway that the 
SHD for a between group (haemic/solid) comparison 
is larger as the SHD for a within group (haemic/haemic 
or solid/solid) comparison.
The comparison within solid tumours can be sum-
marized  as  follows.  It  holds  that  the  breast-colon 
comparison (# of arrays: 1834/197) is only distinct for 
the Wnt signalling pathway (04310). The breast-lung 
comparison (# of arrays: 1834/386) results for most 
pathways in a pronounced difference except the AML 
pathway (05221) and the Mismatch repair pathway 
(03430). The breast-prostate comparison (# of arrays: 
1834/416) shows marginal or non-significant differ-
ences  for  the  p53  signalling  pathway  (04115),  the 
ECM-receptor interaction pathway (04512), the AML 






















Figure 2. SHD in single pathways for comparisons within solid tumours 
(black), haemic tumours (red) and between group comparisons (blue).
Table 3. SHDs (permutation P-values) for different hemic and solid cancer entities and pathways.
solid entities
BRe-cOL BRe-LUn BRe-pRO cOL-LUn cOL-pRO LUn-pRO
04110 577 (0.302) 642 (,0.002) 627 (,0.002) 435 (,0.002) 420 (,0.002) 477 (,0.002)
04115 319 (0.994) 373 (,0.002) 350 (0.046) 234 (,0.002) 223 (0.016) 279 (,0.002)
04210 475 (0.054) 540 (,0.002) 475 (,0.002) 335 (,0.002) 298 (0.02) 375 (,0.002)
04310 834 (,0.002) 919 (,0.002) 920 (,0.002) 617 (,0.002) 568 (,0.002) 701 (,0.002)
04512 435 (0.993) 477 (,0.002) 453 (0.614) 314 (0.686) 310 (0.592) 354 (0.802)
05210 506 (0.524) 569 (,0.002) 549 (,0.002) 393 (,0.002) 351 (,0.002) 428 (,0.002)
05215 527 (0.998) 607 (,0.002) 596 (0.002) 416 (,0.002) 387 (0.046) 457 (0.002)
05221 279 (0.993) 322 (0.044) 312 (0.84) 235 (0.136) 215 (0.374) 272 (0.008)
05223 314 (0.644) 336 (,0.002) 313 (0.162) 222 (0.038) 213 (0.028) 241 (0.022)
04150 234 (0.418) 242 (,0.002) 268 (,0.002) 172 (,0.002) 170 (,0.002) 180 (0.004)
03410 89 (0.744) 107 (,0.002) 107 (,0.002) 68 (,0.002) 68 (,0.002) 76 (,0.002)
03420 145 (0.35) 163 (,0.002) 146 (,0.002) 114 (,0.002) 109 (,0.002) 107 (,0.002)
03430 60 (0.993) 73 (0.054) 61 (0.918) 63 (0.006) 45 (0.366) 62 (0.188)
Hemic entities
ALL-AML ALL-cLL ALL-LYM AML-cLL AML-LYM cLL-LYM
04110 581 (,0.002) 542 (,0.002) 570 (,0.002) 447 (,0.002) 453 (,0.002) 436 (,0.002)
04115 300 (,0.002) 283 (0.142) 266 (0.066) 241 (,0.002) 240 (,0.002) 193 (0.128)
04210 438 (,0.002) 373 (0.118) 393 (,0.002) 345 (,0.002) 383 (,0.002) 296 (0.004)
04310 822 (,0.002) 697 (0.05) 761 (,0.002) 585 (,0.002) 675 (,0.002) 526 (,0.002)
04512 468 (0.004) 435 (0.993) 443 (0.544) 373 (0.658) 381 (,0.002) 338 (0.52)
05210 503 (,0.002) 424 (0.644) 472 (,0.002) 389 (,0.002) 413 (,0.002) 336 (,0.002)
05215 516 (,0.002) 470 (0.994) 506 (0.006) 410 (0.23) 440 (,0.002) 344 (0.562)
05221 265 (0.002) 242 (0.994) 261 (0.008) 233 (0.386) 248 (,0.002) 195 (0.232)
05223 307 (,0.002) 255 (0.868) 258 (0.02) 234 (0.014) 249 (,0.002) 193 (0.038)
04150 241 (,0.002) 223 (0.06) 225 (,0.002) 192 (,0.002) 200 (,0.002) 162 (0.002)
03410 104 (,0.002) 85 (0.012) 91 (,0.002) 83 (,0.002) 91 (,0.002) 76 (,0.002)
03420 132 (,0.002) 123 (0.034) 131 (,0.002) 125 (,0.002) 133 (,0.002) 100 (,0.002)
03430 62 (0.002) 63 (0.758) 63 (,0.002) 61 (0.062) 59 (0.042) 48 (0.628)Large meta-analysis in oncology
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pathway (05221), Non-small cell lung cancer pathway 
(05223), and the Mismatch repair pathway (03430). 
The colon-lung comparison (# of arrays: 197/386) 
shows marginal or non-significant differences for the 
ECM-receptor interaction pathway (04512), the AML 
pathway (05221), and the   Non-small cell lung cancer 
pathway (05223). The colon-prostate comparison (# of 
arrays: 197/416) shows marginal or non-significant 
differences for the p53 signalling pathway (04115), 
Apoptosis  (04210),  the  ECM  receptor  interaction 
pathway (04512), Prostate cancer pathway (05215), 
the AML pathway (05221), Non-small cell lung can-
cer pathway (05223), and the mismatch repair path-
way  (03430).  The  lung-prostate  comparison  (#  of 
arrays: 386/416) shows marginal or non-significant 
differences  for  ECM-receptor  interaction  pathway 
(04512), Non-small cell lung cancer pathway (05223), 
and the Mismatch repair pathway (03430).
The  comparison  within  haemic  tumours  can  be 
summarized as follows. The ALL-AML comparison 
(# of arrays: 916/534) shows for each pathway a dis-
tinct conditional correlation structure. The ALL-CLL 
comparison (# of arrays: 916/177) shows marginal or 
non-significant differences for all pathway except Cell 
cycle (04110). The ALL-LYM (# of arrays: 916/331) 
comparison shows marginal or non-significant differ-
ences for p53 signalling (04115), ECM-receptor inter-
action (04512), Non-small cell lung cancer (05223). 
The AML-CLL comparison shows marginal or non-
significant differences for the ECM receptor interac-
tion (04512), Prostate cancer (05215), AML (05221), 
Non-small cell lung cancer (05223), and mismatch 
repair (03430). Comparing AML-LYM (# of arrays: 
534/331) shows only the Mismatch repair pathway 
(03430) as marginal significant. The CLL-LYM com-
parison (# of arrays: 177/331) shows marginal or non-
significant  differences  for  p53  signalling  (04115), 
ECM-receptor  interaction  (04512),  Colon  cancer 
(05210),  Prostate  cancer  (05215),  AML  (05221), 
Non-small cell lung cancer (05223), and Mismatch 
repair (03430).
Table 6 in the Appendix presents the SHD and 
P-values for the between groups comparisons. They 
result in distinctive conditional correlation structures 
in all pathways for most of the pairs. More than two 
marginal  or  non-significant  P-values  are  found  in 
the COL-CLL, COL-LYM, LUN-ALL comparisons 
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the COL-CLL comparison is found for p53 signalling 
(04115), Apoptosis (04210), ECM-receptor interac-
tion (04512), Prostate cancer (05215), AML (05221), 
Non-small cell lung cancer (05223), mTOR signalling 
(04150),  Base  excision  repair  (03410),    Nucleotide 
excision repair (03420), and Mismatch repair (03430) 
pathway. No clear evidence for a difference in the 
COL-LYM comparison is found for p53 signalling 
(04115), ECM-receptor interaction (04512),   Prostate 
cancer (05215), AML (05221), Non-small cell lung 
cancer  (05223),  mTOR  signalling  (04150),  and 
  Mismatch repair (03430). Finally, no clear evidence 
for  a  difference  in  the  COL-CLL  comparison  is 
found for p53 signalling (04115), Apoptosis (04210), 
ECM-receptor  interaction  (04512),  Prostate  cancer 
(05215), AML (05221), Non-small cell lung cancer 
(05223),  mTOR  signalling  (04150),  Base  excision 
repair (03410), Nucleotide excision repair (03420), 
and mismatch repair (03430) pathway.
We use the number of pathways with no evidence 
for differential conditional correlation structure as a 
measure for similarity between tumor entities. Table 4 
and Figure 3 summarize the situation. Table 5 lists the 
number of comparisons between and within groups 
with a permutation P-value above 0.1. The highest 
ranked pathways with respect to no evidence for a dif-
ference are Mismatch repair (03430), Non-small cell 
lung cancer (05223), AML (05221),   ECM-receptor 
interaction  (04512),  and  p53  signalling  (04115) 
  pathway. The pathways Cell cycle (04110) and Wnt 
signalling (04310) show in all except one compari-
son a significant difference in conditional correlation 
structure.
The major similarity between the entity pairs are 
visualized in Figure 3. Every node represents an entity 
and the wide of the edges is the number of pathways 
with no evidence for a difference. Similar pathway 
structure can be found between ALL-CLL, BREAST-
COLON, and COLON-CLL. In the haemic tumour enti-
ties there is a noticeable similarity between   lymphatic 
tumours (ALL, CLL, Lymphoma). In the solid tumour 
entities there is a similarity between tumours (breast, 
colon, prostate) arising in gland tissues.
Discussion
Similarities as well as dissimilarities between cellular 
processes in different tumour entities are of general 
interest. They promise a better understanding of basic 
disease mechanism as well as therapeutic principles. 
To this end many studies are concerned with the com-
parison of transcription profiles and gene signatures.4 
Bioinformatic tools give easy access to a wide range 
of signatures36 and help to validate them over a wide 
range of disease entities. For example the molecular 
program of normal wound healing plays an important 
role in cancer metastasis. Consistent features in the 
transcriptional response of normal fibroblasts to serum 
reveal links between wound healing and cancer pro-
gression in a variety of common epithelial tumours.37
Our studies does not focus on transcription pro-
files but on the structure of wiring between genes 
annotated to specific pathways and if these structures 
differ between tumor entities. We formalize the wir-
ing between genes by conditional correlation graphs28 
where the genes of interest define the nodes and a 
direct influence between two genes is represented by 
an edge.
The following ideas motivated the study:
•	 Tumours  of  different  tissues  may  have  distinct 
features  in  the  way  the  corresponding  transcrip-
tion of genes annotated to the pathways is regu-
lated. Therefore,  we  compared  haemic  and  solid 
tumours. Within both groups we defined two sub-
groups. Solid tumours were split in a group taken 
from gland (breast, colon, and prostate cancer) and 
lung tissue. Haemic tumours were split in lymphatic 
tumours (ALL, CLL, and Lympoma) and AML.
•	 To  detect  similar  regulation  structures  in  major 
pathways  between  cancers,  we  studied  generic 








Figure  3.  Similarity  between  tumours  in  terms  of  pathways  with  no 
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(Cell cycle,  Apoptosis, p53 signalling, ECM-receptor, 
Wnt signalling), which are disease related (Colorectal 
cancer, Prostate cancer, Non-small cell lung cancer, 
AML), and finally pathways which concern DNA 
repair.
The study is designed as a meta-analysis of data 
available in public repositories. Uses microarrays from 
one specific technical platform (HG-U133A) to avoid 
unnecessary heterogeneity caused by   differing tech-
nical and lab-specific conditions. The data collection 
was the most challenging part of the   meta-analysis. 
Our activity focused on the ArrayExpress   repository. 
Here we found 61 studies with a total of 5693 arrays 
(HG-U133A) arrays which contributed material to the 
tumours of interest. A total of 101 defect arrays and 
further 801 duplicates of microarrays were removed. 
The package   ArrayExpressDataManage was devel-
oped to organise the data management of the 4791 
remaining microarrays for the   meta-analysis. The pack-
age allows an efficient and reproducible retrieval of 
large data sets from the ArrayExpress repository.
The quality of the downloaded data in terms of 
phenotype information was very low. It is astonishing 
that other authors do not report this fact. Phenotype 
information is generally missing and even incomplete 
in basic items to characterize the clinical staging of 
tumours. Our data was taken from clinical studies 
and only 64% of the studies provided the sex of the 
patients. Age was missing in 50% of the patients. 
Detailed information on the tumour (tumour grade 
was available in 20% of the solid cancer, only sparse 
information on metastatic disease) was not given.
All studies contributed to ArrayExpress declare for-
mally compliance with the MIAME criteria.38 MIAME 
also requests information on the biological properties 
of  the  samples  and  phenotypes  that  were  assayed. 
Neglecting this information may produce an insensible 
mixture of probes and invalidates most of the public 
oncological microarray data for secondary research.
The missing phenotype information confronts us 
with a potentially inhomogeneous set and a biologi-
cal mix of probes within a tumour entity which are in 
different stages of its development. This confounding 
may invalidate the interpretation of our results.
Furthermore, the observed microarray data quanti-
fies time averages of a complex dynamics with many 
components. Additionally, the gene expression mea-
sured for a few selected genes annotated to a pathway 
is only a small observation window on the system. 
The unobserved components also may confound the 
conditional correlation between two observed genes.
All these restriction impose a severe restrictions on 
interpretability and only allow a very coarse conclu-
sion if a difference between two conditional correlation 
graphs is assessed: The dynamics are somehow distinct. 
Techniques to locate differences between two graphs 
more precisely to specific subset of nodes of graphs 
are under study and applied in settings with a stricter 
control of the phenotype and the confounding.16
The estimation of conditional correlation s  tructures 
was performed with the PC-Algorithm.28 The   difference 






solid tumors  
6 comparisons
Haemic tumors  
6 comparisons
Mixed tumors  
16 comparisons
3410 3 1 1 1
3420 4 1 1 2
3430 15 5 4 6
4110 1 1 0 0
4115 10 3 3 4
4150 5 1 1 3
4210 5 2 1 2
4310 1 0 1 0
4512 11 5 4 2
5210 2 1 1 0
5215 5 2 3 2
5221 13 5 3 5
5223 13 5 4 4Schmidberger et al
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between the estimated   structures was quantified by 
the Structural Hamming   Distance. Statistical signifi-
cance was explored by   resampling techniques. The 
  computational challenge were handled by a parallel-
ized computation environment created out of standard 
open access tools from R and the Bioconductor.18,19 
Additional software which was required to build up 
our pipeline for reproducible calculations is readily 
provided.
The  quantitative  results  for  the  conditional 
  correlation  structures  of  the  gene  sets  and  tumour 
quantities  studied  can  be  summarized  as  follows: 
The  inferred  structures  for  the  selected  thirteen 
pathways look mostly similar between breast cancer 
and colon cancer as well as between ALL and CLL 
samples. The lag of strong differences in the struc-
tures between colon cancer and CLL samples never 
addressed to our knowledge in the literature. There 
are narrative reports on patients with two different 
primary tumours where the treatment directed two 
one of both only resulted in a response of the second 
and not the first (in our centre a patient with simul-
taneous colon cancer and AML). The pathways with 
the most similar conditional correlation of the anno-
tated genes between tumour entities are Mismatch 
repair (03430), Non-small cell lung cancer (05223), 
and AML (05221). The wiring between genes anno-
tated to the Wnt pathway (04512) seems to be more 
similar within as between the tumour entities (solid/
haemic).
The study answers both heuristics which motivated 
the meta-analysis in a limited way. It defined the tech-
nical requirements to perform a meta-analysis with 
about 4800 microarrays. Also, the statistical methods 
are available which help to tackle the question posed. 
But, it was not possible to enrich the developed anal-
ysis pipeline with necessary biological and clinical 
data. The publicly available data generally lack rele-
vant and important phenotype information. The sober-
ing experience of our study asks for combined efforts 
to improve the data quality in public repositories for 
data from high-throughput technologies.
The dataset used for the presented results is from 
February  2009.  Since  then,  only  7  new  data  sets 
became available which meet our inclusion/exclusion 
  criteria:  six  for  breast  cancer  and  1  for  prostate 
cancer, all together about 550 arrays. Furthermore, 
it would have been possible to validate our findings 
on  microarray  data  derived  from  microarray  type 
HGU-133 Plus 2.0. We did not perform the   validation 
since  we  are  not  able  to  assure  the  homogeneity 
between the populations used for the first step and 
the validation. In this case we would not be able to 
discuss  possible  deviations  between  the  validation 
based on the HGU-133 Plus 2.0 and the calculation 
based on the HGU-133 arrays. The HGU-133 Plus 2.0 
arrays are more recent as the HGU-133 arrays which 
may imply that the studies based on the HGU-133 
Plus 2.0 array are performed with more specific ques-
tions on more specific populations.
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Appendix
Methodological considerations  
for the interpretation of our results
A short outline of ideas is given on how to relate bio-
logical ideas to the results of the described microar-
ray analyses.
There are two problems: measuring time averages 
on a narrow set of dynamic processes and confound-
ing of interaction within genes annotated to a path-
way by unobserved quantities.
In order to understand the problem of time aver-
age, the cell is considered as a large dynamic system 
which is in a stable state. The multivariate process 
(Xt)t∈[0,T ] describes the dynamic of all entities within 
the cell over a time period of length T. The data read 
from  a  microarray  is  the  average  over  many  cells 
caught at different time points within the dynamics 
of the cell-specific system. If the dynamic system is 
ergodic, its behaviour when it is allowed to run for a 
long time can be read from the cross-sectional mea-
surements of many simultaneously trajectories at a 
fixed time point. This is expressed through ergodic 
theorems which assert that, under certain conditions, 
the time average of a function along the trajectories 
exists almost everywhere and is related to the space 
average.39
Therefore, if a large amount of cells is assayed 
we get an average of all measurements from each 




Xd t t = ∫
1
The  covariance  matrix  of  the  high-dimensional 
vector W consists of integrals of covariance (in the 
diagonal) as well as cross-covariance functions (off 
diagonal).  The  term  cross-covariance  refers  to  the 
covariance cov(X,Y ) between two random vectors X 
and Y. In order to distinguish that concept from the 
“covariance” of a random vector X, which is under-
stood to be the matrix of covariance between the sca-
lar components of X.
If W is observed in the tissue of several individ-
uals, it is possible to estimate the conditional cor-
relation structure of W by a conditional correlation 
graph. If material from a different biological condi-
tion exists, one could estimate a second graph and 
compare both. In case of a difference between both 
graphs  the  conclusion  is  allowed  that  the  corre-
sponding covariance matrices are different and that 
also some time averages of cross-covariance func-
tions between components of the cell dynamics are 
different. This would allow the vague statement that 
the dynamic system under one condition is different 
from the dynamic system which governs the alterna-
tive condition. A deeper insight given such data is 
not possible.
The next problem is that we do not see the com-
plex  dynamic  system.  Transcription  measurements 
are only available for a restricted set of genes (defined 
by the pathway). We do not see the whole of W but 
only a small subset of it. Let U be the components of 
W which are observable from the data and V be the 
components of W which are not measured (protein 
concentration, gene expression of genes which are 
not part of our pathway, …).
Often a random dynamical system is considered 
as a complex Gaussian process and the framework 
of multivariate normal distributions is available to 
do a thorough formal analysis. Thereby, the preci-
sion matrix of W which is the inverse of the covari-
ance matrix plays the central role to understand direct 
interactions between the components.
Using  this  approach  allows  to  understand  how 
the  unobserved  components  influence  the  correla-
tion structure of the observed data by confounding. 
Confounding means that the conditional correlation 
between two genes is also the effect of unobserved 
components  in  the  system  and  possibly  not  a  real 
biological feature that is shared by both genes. This 
makes it difficult to interpret a conditional correla-
tion graph of genes annotated to a pathway. It may 
show effects caused from outside and not by biologi-
cal activity within the pathway.
The precision matrix of W is given by Q and can 
be partitioned in parts QUU and QVV which describe the 
conditional correlation structure in the observed part 
(U    ) and the unobserved part (V   ) of the system. The 
parts QUV and QVU (=  QU
T
V) describe the conditional 
correlation structure between the observed and unob-
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The precision matrix of the marginal distribution 
of the observed components U is given by
QQ QQ Q UU
m
UU UV VV VU
arg =+ . -1
This formalizes the idea that in the worst case an 
observed conditional correlation between two path-
way genes is not caused by activity within the path-
way but transmitted by conditional correlation of the 
genes with components of the system which are not 
observed.  The  following  example  demonstrates  a 
practical consequence of the formal consideration.
A transcription factor regulates the expression of 
gene G1. Transcription factors belong to the unob-
served V components of W. The concentration of a 
transcription factor may be regulated by some other 
protein which is also an unobserved V component 
of W. This protein is regulated by the transcriptional 
products  of  gene  G2.  The  conditional  correlation 
structure of both proteins is an element of QVV while 
the interaction of the transcription factor with G1 and 
the protein regulation by gene G2 are represented by 
elements of QUV . This may imply a non-zero element 
in Q UU
marg without the need for direct interaction of G1 
and G2 within the pathway.
result of permutation test  
between cancer groups
Table 6 presents the SHD and P-values for the between 
groups comparisons. The results in the solid and hae-
mic tumors are available in Table 3 in the paper.
Data set generation script
The data set was created using the new developed 
ArrayExpressDataManage  package  (available  at 
http://AEDataManage.R-forge.R-project.org/).  The 
following commands (and experiments) were used to 
generate the locale data set structure:
R> library(ArrayExpressDataManage)
R> # Solid tumors
R> path_solid <- createDataStruct(path=‘/home/cancdat’,
+  data=list(
+   breast=c(‘E-GEOD-6532’, ‘E-GEOD-4922’, ‘E-GEOD-1456’,
+   ‘E-GEOD-11121’, ‘E-GEOD-7390’, ‘E-GEOD-12093’, ‘E-GEOD-2603’,
+   ‘E-GEOD-5462’, ‘E-GEOD-9936’, ‘E-GEOD-5847’, ‘E-MTAB-7’,
+   ‘E-GEOD-1561’, ‘E-TABM-43’, ‘E-MEXP-440’, ‘E-GEOD-11965’,
+   ‘E-GEOD-6772’, ‘E-GEOD-9574’, ‘E-GEOD-4917’, ‘E-GEOD-3494’,
+   ‘E-GEOD-2990’),
+    #E-GEOD-6883 to small
+    #E-TABM-244 included in E-MTAB-7
+   prostate=c(‘E-GEOD-8218’, ‘E-TABM-26’, ‘E-TABM-90’, ‘E-MEXP-1327’,
+   ‘E-GEOD-2443’),
+   colon=c(‘E-MTAB-57’, ‘E-GEOD-4045’, ‘E-MEXP-383’, ‘E-MEXP-101’,
+   ‘E-GEOD-2742’, ‘E-MEXP-833’),
+   lung=c(‘E-GEOD-4824’, ‘E-GEOD-10072’, ‘E-GEOD-6253’, ‘E-GEOD-7670’,




R> path_hemic <- createDataStruct(path=‘/home/cancdat’,
+   data=list(
+   cll=c(‘E-GEOD-11038’, ‘E-GEOD-8835’, ‘E-GEOD-6691’),
+   #E-GEOD-9992 included in E-GEOD-11038 (super series)
+   aml=c(‘E-GEOD-12417’,’E-GEOD-1159’,’E-GEOD-9476’, ‘E-GEOD-1729’),
+   #E-GEOD-8970 defect annotation fileSchmidberger et al
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+   all=c(‘E-GEOD-12995’,’E-GEOD-635’, ‘E-GEOD-10255’, ‘E-GEOD-2351’,
+   ‘E-GEOD-3912’, ‘E-MEXP-313’, ‘E-GEOD-14618’, ‘E-TABM-125’,
+   ‘E-GEOD-4698’, ‘E-GEOD-8879’, ‘E-MEXP-120’, ‘E-GEOD-1577’),
+   #E-GEOD-14613 included in E-GEOD-14618
+   #E-GEOD-3910 and E-GEOD-3911 included in
+   #E-GEOD-3912 (super series)
+   #E-GEOD-643–660 included in E-GEOD-635 (super series)
+   lymphoma=c(‘E-GEOD-4475’,’E-TABM-346’,’E-TABM-117’, ‘E-GEOD-8388’)
+   #E-GEOD-4176 is to small
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Figure 4. Legend for KeGG edges (http://www.genome.jp/kegg/document/
symbols.gif).
Legend for KeGG graphs
Figure 4 describes the arrows in the KEGG graphs.
Arrayexpress experiments selected  
for the meta-analysis
Tables  7–17  list  all  selected AE  experiments  used 
in the meta-analysis case study (grouped by cancer 
entities).Large meta-analysis in oncology











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1Large meta-analysis in oncology






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5Large meta-analysis in oncology




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1Large meta-analysis in oncology













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1Large meta-analysis in oncology















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3Large meta-analysis in oncology































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Large meta-analysis in oncology
Bioinformatics and Biology Insights 2011:5  39